SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.
about
Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy.The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetesMass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer.A robust meta-classification strategy for cancer detection from MS data.Early diagnostic protein biomarkers for breast cancer: how far have we come?Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy.Proteomic analysis of childhood leukemia.SELDI-TOF-MS proteomics of breast cancer.The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasmaApplication of serum protein fingerprint in diagnosis of papillary thyroid carcinoma.Serum protein patterns in newly diagnosed type 2 diabetes mellitus--influence of diabetic environment and family history of diabetes.Clinical proteomics in breast cancer: a review.Immuno-MALDI-TOF MS: new perspectives for clinical applications of mass spectrometry.Increased expression of histone proteins during estrogen-mediated cell proliferation.Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.Mining novel biomarkers for prognosis of gastric cancer with serum proteomicsInflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins.Detection and identification of potential biomarkers of breast cancer.Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients.The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer.Challenges to developing proteomic-based breast cancer diagnostics.Clinical proteomics of breast cancerIdentification of serum protein markers for breast cancer relapse with SELDI-TOF MS.Protein biomarkers for the early detection of breast cancer.Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment.Diagnostic and prognostic role of serum protein peak at 6449 m/z in gastric adenocarcinoma based on mass spectrometryMass spectrometry in clinical proteomics - from the present to the future.Evaluation of IGF-I levels and serum protein profiles of diabetic cats and dogs.Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling.Cancer biomarker discovery via low molecular weight serum proteome profiling - Where is the tumor?Antibody and Reverse Capture Protein Microarrays for Clinical Proteomics
P2860
Q24817009-CC41AB0F-6630-4572-8623-2F7B0B422999Q30828348-BB557A0B-B832-446C-B949-FC0FA5276C6BQ30985472-97DA01A0-02A2-4941-BE2C-B00B1E1586BCQ31024840-FCDB7897-55E8-4E88-9C9D-8CBB6FCC8D4FQ31043570-DADD797E-6F65-437B-BE5C-DC00D9732F64Q31095551-E745DA09-F034-42DC-8013-D11E5CF640B3Q33222672-4CC0FC1C-12F1-44B6-BA2F-4FCD83650E1EQ33227849-5D2AEE47-EA55-401C-A5EC-8A9DAB0AF7BCQ33233126-34BA1F9D-7A4F-47FB-9C46-9FF1CAA6AB8DQ33255788-8767B6E2-0758-4F5F-9DBC-B30BE663C30FQ33304304-DE5E2368-F704-45D8-AD9C-F2B54996E19AQ33392976-CE1C7A41-17E4-465B-B3B8-F23A0409D2B9Q33411371-9BFDBA27-DF32-4BF4-B459-D392BAFB6B4FQ33480517-66FF18CB-2E38-4A27-9816-A7A2521F62D7Q33481276-928602FD-E801-4EE8-929E-92067811BAD4Q33501377-79EEF815-20C0-4730-9C17-455524A828C0Q33517207-027A26C8-2AA9-4F8A-9076-D170A445AE77Q33541894-917014E6-B91A-4D75-AA08-DF036CF5A5C8Q33745000-86C0CD24-91FF-4D66-A7C9-2076D5F2B1DEQ33822314-F16B1C7F-EC50-4FAE-B1D1-8A9E0654536BQ33823926-AB1295E1-5003-4123-BDF1-A607C0F6331DQ33885885-4668FDF6-F1A9-4B2E-B9E8-8DF18EE74BA7Q33891208-12B5A4A3-3CC8-4789-805E-75D179050460Q35367572-7A9E1DFA-4C67-4736-8CA2-EA33120F0493Q35637149-21D36C9E-10C9-4D9D-9D8A-6A27D496231EQ36147848-3B44E515-6A03-4BD8-BA4D-591930FFFBBBQ37174708-6F51DC96-5F1D-4687-AA88-B8976A00FEA5Q37817258-EACDE948-A01B-4B09-ABAA-979F7CEC61E8Q39649512-0BC2E46B-94C3-4DFD-82A4-DD3644ADD6C3Q42230129-09F4CD2E-4A80-44AB-B799-FCBB27C98519Q47259472-DE40D5FD-8DD0-4CCA-923C-65C748FE56EFQ57952030-14C25CAA-1005-492F-B434-47B9425932D3
P2860
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.
@en
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.
@nl
type
label
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.
@en
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.
@nl
prefLabel
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.
@en
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.
@nl
P2093
P356
P1433
P1476
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers
@en
P2093
Betsy Gregory
Christine Laronga
George L Wright
Henry Lynch
O John Semmes
Patrice Watson
Richard R Drake
Roger R Perry
Stephen Becker
P304
P356
10.1155/2004/759530
P577
2003-01-01T00:00:00Z